<DOC>
	<DOCNO>NCT02049138</DOCNO>
	<brief_summary>This Phase 2 , multicenter , open-label extension study RA subject .</brief_summary>
	<brief_title>An Open-label Extension Study Evaluating Safety Efficacy ABT-494 Rheumatoid Arthritis Subjects</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>1 . Subjects complete Study M13550 Study M13537 ABT494 develop discontinuation criterion . 2 . If subject evidence new latent Tuberculosis ( TB ) infection , subject must initiate complete minimum 2 week ( per local guideline , whichever long ) ongoing TB prophylaxis continue receive study drug . 3 . If female , subject must meet one follow criterion : Postmenopausal ( define menses least 1 year ) . Surgically sterile ( bilateral oophorectomy hysterectomy ) . Practicing time screen least 30 day last dose study drug least TWO follow method birth control : 1 . Tubal ligation 2 . Partner vasectomy ( least 6 month earlier ) ( vasectomized male partner sole partner female subject ) 3 . Intrauterine device 4 . A male condom spermicidal jelly cream 5 . Diaphragm , contraceptive sponge cervical cap spermicidal jelly cream 6 . Hormonal contraceptive ( inject , oral , transdermal implant method ) must take least 2 month prior dose 4 . Male subject must agree follow protocolspecified pregnancy avoidance measure , include refrain donate sperm , 30 day post last dose study drug . 5 . Subjects must voluntarily sign date inform consent , approve Independent Ethics Committee ( IEC ) /Institutional Review Board ( IRB ) , prior initiation screen study specific procedure . 1 . Pregnant breastfeed female . 2 . Ongoing infection Week 0 NOT successfully treat . Subjects ongoing infection undergo treatment may enrol BUT NOT dose infection successfully treat . 3 . Anticipated requirement receipt live vaccine study participation include 30 day last dose study drug . 4 . Laboratory value visit immediately prior Baseline Visit meeting follow criterion : Serum aspartate transaminase ( AST ) alanine transaminase ( ALT ) &gt; 3.0 × Upper Limit Normal ( ULN ) Estimated glomerular filtration rate simplify 4variable Modification Diet Renal Disease ( MDRD ) formula &lt; 40mL/min/1.73m2 Total white blood cell count ( WBC ) &lt; 2,000/μL Absolute neutrophil count ( ANC ) &lt; 1,000/μL Platelet count &lt; 50,000/μL Absolute lymphocyte count &lt; 500/μL Hemoglobin &lt; 8 gm/dL 5 . Enrollment another interventional clinical study participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Joint Diseases</keyword>
	<keyword>Musculoskeletal Disease</keyword>
	<keyword>Anti-inflammatory Agents</keyword>
	<keyword>Antirheumatic agent</keyword>
	<keyword>Arthritis</keyword>
</DOC>